First patients dosed in Phase 1a clinical trial of UCL-backed G-Quadruplex (G4) targeting treatment for solid tumors, including pancreatic cancer
Sygnature Discovery
NOVEMBER 29, 2023
It was conceived, invented and developed by Professor Stephen Neidle and his team in the School of Pharmacy at University College London with the involvement of Sygnature Discovery scientists. They anticipate providing an update on safety and preliminary efficacy of the Phase 1a study in the first half of 2024.
Let's personalize your content